Karwaciak, I.; Karaś, K.; Sałkowska, A.; Pastwińska, J.; Ratajewski, M.
Chlorpromazine, a Clinically Approved Drug, Inhibits SARS-CoV-2 Nucleocapsid-Mediated Induction of IL-6 in Human Monocytes. Molecules 2022, 27, 3651.
https://doi.org/10.3390/molecules27123651
AMA Style
Karwaciak I, Karaś K, Sałkowska A, Pastwińska J, Ratajewski M.
Chlorpromazine, a Clinically Approved Drug, Inhibits SARS-CoV-2 Nucleocapsid-Mediated Induction of IL-6 in Human Monocytes. Molecules. 2022; 27(12):3651.
https://doi.org/10.3390/molecules27123651
Chicago/Turabian Style
Karwaciak, Iwona, Kaja Karaś, Anna Sałkowska, Joanna Pastwińska, and Marcin Ratajewski.
2022. "Chlorpromazine, a Clinically Approved Drug, Inhibits SARS-CoV-2 Nucleocapsid-Mediated Induction of IL-6 in Human Monocytes" Molecules 27, no. 12: 3651.
https://doi.org/10.3390/molecules27123651
APA Style
Karwaciak, I., Karaś, K., Sałkowska, A., Pastwińska, J., & Ratajewski, M.
(2022). Chlorpromazine, a Clinically Approved Drug, Inhibits SARS-CoV-2 Nucleocapsid-Mediated Induction of IL-6 in Human Monocytes. Molecules, 27(12), 3651.
https://doi.org/10.3390/molecules27123651